Exelixis Pushes Ahead
April 25th, 2007
Drug development is never a smooth process. Last year, Rule Breakers pick Exelixis (Nasdaq: EXEL) experienced a setback with its lead developmental compound, potential cancer treatment XL999. Yesterday, Exelixis announced that the FDA has allowed it to resume testing of the drug and that it was initiating a phase 1 trial in patients with non-small cell lung cancer.